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Cancer patients are at increased risk of persistent depressive and anxiety symptoms and disor-
ders compared to the general population. However, these issues are not always identified,
whichmayworsen the prognosis and increasemorbidity andmortality. Therefore, the objectives
of this study are to identify predictor variables (demographic and clinical) for the development of
mood and anxiety disorders in cancer outpatients and to propose a probabilistic screening pro-
tocol considering these variables and certain standardized screening instruments.
Methods
A total of 1,385 adults, of both genders, receiving outpatient cancer care were evaluated
using a questionnaire and screening instruments. Thereafter, 400 of these subjects
responded to the Structured Clinical Interview for the Diagnostic and Statistical Manual of
Mental Disorders, Fourth Edition (SCID-IV) by telephone to confirm or rule out the presence
of a Current Major Depressive Episode (CMDE) or Anxiety Disorder (AD).
Results
Of the patients surveyed, 64%met the criteria for CMDE and 41% for AD. Female gender
was found to be a risk factor for both disorders, and the presence of previous psychiatric his-
tory and marital status (divorced and widowed) were risk factors for anxiety disorders.
When scoring above the recommended cutoff score, the screening instruments also indi-
cated a risk of the studied disorders. Based on these findings, a screening protocol and
nomograms were created for the quantification, combination and probabilistic estimate of
risk, with accuracy indicators >0.68.
Conclusion
The prevalence rates for the disorders under study are extremely high in cancer patients.
The use of the proposed protocol and nomogram can facilitate rapid and wide screening,
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thus refining triage and supporting the establishment of criteria for referral to mental health
professionals, so that patients can be properly diagnosed and treated.
Introduction
Compared with the general population, cancer patients are at increased risk of persistent
depressive and anxiety disorders and symptoms. These conditions may appear as a reaction to
the diagnosis itself and/or throughout the treatment and rehabilitation processes [1] because
cancer patients experience different types of loss and different levels of stress and emotional
distress [2].
Likewise, the deterioration in physical appearance, disability and life changes associated
with clinical disease are also risk factors for psychiatric disorders, particularly in individuals
with a family history thereof [3]. There are also clinical conditions associated with cancer that
can lead to the emergence of such symptoms [4,5].
Depression is the most common psychiatric disorder in cancer patients, with prevalence
rates ranging from 13% to 40% [6,7]. This condition is associated with a worse prognosis for
cancer treatment and increased morbidity and mortality [8]. Similarly, the prevalence of anxi-
ety in cancer patients can vary between 10% and 30% [9,10].
Despite these high prevalence rates, there are many barriers to the identification and treat-
ment of these disorders. Such barriers include the overlapping of emotional and clinical symp-
toms, the lack of preparation/training of healthcare professionals who are not specialized in
mental health for evaluating emotional/psychological symptoms, the limited time for research-
ing these matters, the difficulty involved in accessing specialized psychiatric care, and even the
clinical and emotional distortion of the patients for critically evaluating their emotional state
and seeking help [11].
Thus, establishing predictors of psychiatric disorders in cancer patients and being able to
screen for them can facilitate their early recognition and treatment, which is necessary and
important for better management of oncological diseases and for improving patients' quality of
life [12].
The evaluation of these aspects has been recommended and implemented in clinical set-
tings, in accordance with the recommendations of the International Psycho-Oncology Society
[13], National Comprehensive Cancer Network [14] and American College of Surgeons Com-
mission on Cancer [15, 16].
Screening instruments and protocols, especially those that are fast and easy to use and that
consider such predictor variables, can be of great help and value, overcoming challenges related
to cost and time and their use by healthcare professionals who are not specialized in mental
health and do not have previous training.
Numerous mental disorder screening scales are available, some of which have been vali-
dated for use in cancer care. However, the sensitivity and specificity of such instruments are
not always measured, and when they are, they do not always prove satisfactory (low sensitivity)
[17]. Moreover, these scales are most often used in isolation, without considering other clinical
and sociodemographic variables possibly associated with symptom onset. Thus, the use of
these instruments does not meet the preconized recommendations for the Implementation of
Distress Screening Programs in Cancer Centers [18] which, in general, points out the need of
short, validated and multidimensionais instruments [19], Additionally, to our knowledge,
there are no protocols available in the literature for mental disorders in cancer patients that
offer a probabilistic estimate of the onset of said disorders, which would enable defining priori-
ties for referral and treatment in specialized services. The available protocols, such as the one
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proposed by Pasquini et al [20], are extensive, and their use is limited to mental health special-
ists with previous training in diagnostic interviews. These characteristics difficult to implemen-
tation and the routine use of them in the different cancer patient care services [19,21].
Given the above, this study was developed to identify predictor variables (demographic and
clinical) for the development of mood and anxiety disorders in cancer outpatients and to pro-
pose a probabilistic screening protocol, considering these variables and certain standardized
screening instruments, that can be used in a quick manner and by different healthcare profes-
sionals who are not specialized in mental health.
Materials and Methods
Subjects
The sample in this study included 400 adult cancer outpatients from a specialized cancer hospi-
tal. The hospital is an outpatient public hospital at which approximately 3,800 new patients
and 45,000 returning patients with differing types of cancer are treated per year. Initially, as
part of a larger study [22], a total of 1,384 patients responded privately and individually to the
screening instruments (exclusion criteria: severe cognitive impairment as qualitatively evalu-
ated by the applicator, and the absence of clinical conditions that would affect responses to the
instruments). Next, approximately one-third of the patients (N = 434) were selected to partici-
pate in a second data collection phase using a random number table. These patients were inter-
viewed by telephone to obtain their response to the SCID-VI, and the presence or absence of a
psychiatric diagnosis was confirmed. This step was conducted by professionals who were
trained to administer the instrument. The calculated diagnostic consistency rate was greater
than 85%. Overall, 34 subjects were not located (exclusion criteria), and the final sample con-
sisted of 400 subjects. This sample is representative of the major sample (p>0.05).
Instruments
The following screening instruments were used for data collection:
1. Patient Health Questionnaire-2 (PHQ-2): A self-administered instrument consisting of two
items rated on a Likert scale of zero (never) to three (almost every day), which aims to
screen for depression indicators [23]. The version validated for the Brazilian population
[24], whose sensitivity and specificity were 1.00 and 0.98, respectively, was used. Recently,
in the cancer context, this instrument showed sensitivity 0.53 and specificity of 0.88 for cut-
off score3. [17]
2. Generalized Anxiety Disorder (GAD-7): A self-administered instrument consisting of seven
items, evaluated on a scale of zero to three, where zero means "never" and three means
"almost every day". This instrument aims to screen for typical indicators of anxiety disorders
experienced over the past two weeks [25]. This study used the version validated for the Bra-
zilian population [26], with internal consistency and reliability values of 0.91. For the onco-
logical context, GAD-7 presented for cutting6 sensitivity of 0.52 and specificity of 0.77
[17].
3. Structured Clinical Interview for DSM-IV (SCID-IV—Clinical Version): An instrument
used for establishing clinical psychiatric diagnoses based on the DSM-IV (Diagnostic and
Statistical Manual of Mental Disorders, Fourth Edition). This instrument has been used as a
“gold standard” in diagnostic validation studies among cancer patients in a range of settings
[27,28]. It consists of a total of ten modules that can be applied independently or in combi-
nation according to the desired objective. Modules A (Mood Disorders) and F (Anxiety
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Disorders) were used for this study [29]. The version used was translated and validated for
use in Brazil [30], and its reliability ranged from 0.61 to 0.90.
4. Sociodemographic and clinical identification questionnaire: This instrument was used to
characterize the sample and encompasses the following variables: age, gender, education
level, marital status, religion, work situation, previous history of psychiatric/psychological
disorders, cancer care specialty, tumor location and stage, previous history of cancer treat-
ment and of other clinical diseases. It is based on self-reported of the subject and in medical
records.
Data collection
As part of the larger study, patients were approached at the time of an outpatient medical visit
and were asked to participate in the study by responding to the screening instruments. At this
stage, the researchers provided a notebook with the instruments and remained available for
any clarification and assistance needed. After completing the questionnaires, subjects were told
they would receive a call to participate in the second phase of the study, at least seven and at
most 14 days after the first stage of data collection. Using a random number table, 400 subjects
were randomly selected for a telephone assessment using the SCID-IV, which was conducted
by two properly trained mental health professionals who were blind to the subjects' scores on
the instruments. The calculated diagnostic consistency rate was greater than 85%.
This study was approved by the local research ethics committee (Comitê de Ética em Pes-
quisa do Hospital de Câncer de Barretos- Fundação Pio XII; Process No. 537/2011), and all
subjects provided written informed consent after being fully informed regarding the research
procedure.
Data analysis
The data were entered into a database by research auxiliary technicians, who were responsible
for anonymizing the data. SPSS statistical software was used for the analyses.
The Chi-square and Student’s t tests were used to determine the association between socio-
demographic and clinical characteristics with the screening scales applied in the first stage and
with the disorders evaluated by the SCID-IV.
Subsequently, multiple logistic regression was used to assess the joint relationship of socio-
demographic characteristics and scales with each SCID-IV disorder. For this purpose, only
characteristics with p-values less than or equal to 0.20 in simple analysis (group comparison)
were selected.
The significance level for all other analyses was set at 0.05.
Nomograms were created to quantify the combination of different risk factors and to
develop a probabilistic estimate of the onset of the disorders studied. R software [31] was used
for this analysis.
Finally, the internal validity of the proposed nomogram was determined using the following
measures: Kolmogorov D-statistic, area under the receiver operating characteristic (ROC)
curve, sensitivity, specificity, positive and negative predictive values, and accuracy. The confi-
dence intervals of these measures were calculated via nonparametric bootstrap with 5000 repli-
cations, using R software.
Results
The sample consisted of 400 subjects of both genders (women: N = 246; 61.5%), predominantly
married (N = 273; 68.4%), with varying degrees of education (incomplete/complete elementary
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education: N = 224; 56%), not active in the labor market (N = 243; 60.9%) and affiliated with
some type of religion (N = 311; 80.6%). These subjects were treated in different cancer special-
ties, the majority in Mastology (N = 70; 17.5%), Upper Digestive Tract (N = 57; 14.3%) and
Head and Neck (N = 54; 13.5%).
Of these patients, 32.5% (N = 130) were stage T1, 80.6% (N = 323) N0 and 90.8% (N = 363)
M0. In total, 34.1% (N = 137) had already undergone chemotherapy, 33.4% (N = 134) had
undergone radiotherapy and 71.9% (N = 288) had undergone surgery.
Of the subjects evaluated, 64 (16%) met the criteria for a diagnosis of Mood Disorder (Cur-
rent Major Depressive Episode—CMDE) and 166 (41%) for Anxiety Disorder (AD—Panic
Disorder, and/or Obsessive Compulsive Disorder, and/or Posttraumatic Stress Disorder, and/
or Generalized Anxiety Disorder and/or Phobias).
Initially, some analyses were performed for comparisons between groups, having as a
parameter the presence/absence of CMDE and AD, as evaluated by the SCID-IV.
Table 1 presents the variables analyzed and their significance level for each group.
Variables with a significance level lower than 0.20 (highlighted in bold in Table 1) were then
selected for each disorder, and a multivariate logistic regression was performed, taking this set
of variables as the initial model. Considering the unsatisfactory results of the initial models,
new models were tested by removing the variables with the lowest significance level one by one
until the final model was reached (Tables 2 and 3).
Table 1. Significance levels of the different variables analyzed for each clinical group (Current Major
Depressive Episode and Anxiety Disorder) and control.
Variable CMDE (n = 64) vs. Control (n = 336) AD (n = 166) vs. Control (n = 234)
Gender p < 0.001 p < 0.001
Education level p = 0.420 p = 0.820
Marital status p = 0.111 p = 0.088
Work situation p = 0.090 p = 0.151
Religion p = 0.970 p = 0.924
Previous psychiatric history p < 0.001 p = 0.001
Family psychiatric history p = 0.088 p = 0.039
Previous psychological care p = 0.004 p = 0.034
PHQ-2 (cutoff 3) p < 0.001 —
GAD-07 (cutoff 10) — p < 0.001
CMDE = Current major depressive episode; AD = Anxiety disorder; vs. = versus; PHQ-2 = Patient Health
Questionnaire-2; GAD-07 = Generalized Anxiety Disorder
doi:10.1371/journal.pone.0149421.t001
Table 2. Final multivariate logistic regression model, with Current Major Depressive Episode as outcome variable.
Variable Category Odds ratio CI < 95% P value
Lower limit Upper limit
Gender Female 1 [ref] - - 0.002
Male 0.294 0.136 0.634
PHQ-2/cutoff 3 No 1 [ref] - - < 0.001
Yes 7.139 3.888 13.108
Constant 0.149 - - < 0.001
PHQ-2 = Patient Health Questionnaire-2; [ref] = reference variable; CI = Conﬁdence interval
doi:10.1371/journal.pone.0149421.t002
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As shown in Table 2, male gender is a protective factor against the development of depres-
sive disorder, reducing the risk by 71%. A score equal to or greater than three on the PHQ-2
instrument is indicative of CMDE because it increases the odds of presenting the disorder by
more than seven-fold, thus evidencing its high screening capacity.
According to Table 3, the male gender is also a protective factor against the development of
anxiety disorders. Men are 59% less likely to develop these disorders than women.
The variables previous psychiatric history and marital status also appeared as risk variables;
subjects with previous psychiatric history were 2.52 times more likely to develop some type of
anxiety disorder than subjects without this history. Divorced and widowed subjects were 3.565
and 2.797 times more likely to develop some type of anxiety disorder than single participants.
A score of 10 on the GAD-07 questionnaire was also identified as a risk indicator, sup-
porting the screening value of this instrument.
Considering all of the data presented, a specific protocol was created for the evaluation of
these disorders. This protocol comprised five items and nomograms for risk assessment, which
are shown in Figs 1–3.
The analysis of the internal validity of the nomograms indicated moderate sensitivity and
high specificity, with accuracy values above 0.68. These data are detailed in Table 4.
In S1 Fig, calibration of measures can be observed through the convergence graphics in
which the measures bootstrap are concentrated around the original mean.
Discussion
The present study showed high rates of CMDE and AD in the sample studied, and those rates
are considerably higher than the prevalence rates for the general Brazilian population (11 and
19.9%, respectively) [32]. These results confirm previous findings in the literature that this
population is at risk for such disorders, either because of their clinical condition or due to the
whole spectrum of psychological conditions associated with the disease and coping with it,
especially for diseases such as cancer, which are commonly associated with ideas of death [11].
The study results indicate the following predictor variables for the development of CMDE
and AD: gender, previous psychiatric history, marital status, and score above the recom-
mended cutoff in the screening instruments used.
Table 3. Final logistic regression model, with presence of Anxiety Disorder as outcome variable.
Variable Category Odds ratio CI < 95% P value
Lower limit Upper limit
Gender Female 1 [ref] - - < 0.001
Male 0.409 0.255 0.655
Previous psychiatric history No 1 [ref] - - 0.028
Yes 2.520 1.105 5.749
Marital status Single 1 [ref] - - 0.032
Married 1.462 0.810 2.638 0.207
Divorced 3.565 1.370 9.278 0.009
Widowed 2.797 1.009 7.749 0.048
GAD-07/cutoff 10 No 1 [ref] - - < 0.001
Yes 3.100 1.793 5.359
Constant 0.470 - - 0.008
GAD-7 = Generalized Anxiety Disorder; [ref] = reference variable; CI = conﬁdence interval
doi:10.1371/journal.pone.0149421.t003
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With regard to gender, women had higher rates of depression and anxiety than men, indi-
cating that being female is considered a risk factor for the development of such disorders. Pre-
vious studies that evaluated the role of gender in this context [33, 34] produced similar results,
especially in the Gynecology and Mastology specialties [35, 36].
One possible explanation for these findings is that depression, considered a disease caused
by genetic factors, stress and social pressure, is more common in women because they often
experience work and responsibility overload due to their multiple duties, combining domestic
work with childcare and often a professional career [37, 38]. This pressure becomes greater
Fig 1. Screening protocol for Current Major Depressive Disorder and Anxiety Disorders in cancer outpatients.
doi:10.1371/journal.pone.0149421.g001
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when facing illness and the inability to perform work activities, which can increase the risk fac-
tor, especially if combined with genetic/biological vulnerability, as studies also suggest that bio-
logical issues can be another possible explanation for the differences in depression and anxiety
rates between the two genders [33, 39, 40].
Regarding the presence of previous psychiatric history, it is known that individuals with a
history of psychiatric disorders, particularly if not treated properly, may be more susceptible to
the onset of new disorders [41, 42]. Hereditary and constitutional factors, evaluated through
family psychiatric history, may also influence the development of psychiatric disorders, which
could explain the incidence of the same disorder in different members of a family. This feature
can also be explained by the influence of the environment where these individuals live, as they
share similar habits and are exposed to the same environmental and cultural factors [43, 44].
This variable had predictive value only for the development of anxiety disorders and not for
depression. Nevertheless, in the group comparison, individuals with a previous psychiatric his-
tory also had higher rates of depressive symptoms, indicating its association with the onset of
both symptoms and/or disorders, but with different weights.
The influence of themarital status variable on the onset of anxiety disorders was also identi-
fied in other studies. It is believed that the absence of a spouse and/or partner may increase the
prevalence of anxiety and depression symptoms, as the help of the spouse and/or family and
friends creates a support network that can help to strengthen the patient emotionally and help
him or her adapt to the disease and treatment [45–47].
Regarding the instruments, the presence of a score above the cutoff value was also highly
predictive of the onset of the studied disorders, which underlines the screening power of these
instruments as shown in previous studies, including studies focusing on the cancer population
[48, 49]. The easy, fast and wide-ranging use of these instruments may facilitate the
Fig 2. Nomogram: Risk factors for current depressive episode development.
doi:10.1371/journal.pone.0149421.g002
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Table 4. Indicators of Internal Validity of Nomograms.
ANXIETY DEPRESSION
Statistic Conﬁdence Interval -95% * Statistic Conﬁdence Interval -95% *
Inferior Superior Inferior Superior
D Statistic 0.316 0.248 0.409 0.415 0.309 0.547
PPV 0.656 0.567 0.734 0.466 0.354 0.582
NPV 0.693 0.636 0.743 0.908 0.875 0.939
Sensitivity 0.488 0.411 0.562 0.531 0.407 0.656
Speciﬁcity 0.819 0.762 0.861 0.884 0.85 0.918
Accuracy 0.682 0.633 0.722 0.828 0.79 0.863
ROC curve 0.711 0.659 0.761 0.771 0.711 0.829
* Via Bootstrap non-parametric
PPV = Positive predictive value; NPV = Negative predictive value
doi:10.1371/journal.pone.0149421.t004
Fig 3. Nomogram: Risk factors for anxiety disorder development.
doi:10.1371/journal.pone.0149421.g003
Depression and Anxiety in a Cancer Context
PLOS ONE | DOI:10.1371/journal.pone.0149421 March 8, 2016 9 / 13
identification of potential cases to be referred for evaluation by a specific professional and
treated if necessary.
The proposed protocol was developed from the conjunction of predictor variables, which
are associated with a nomogram providing a probabilistic estimate of the onset of disorders. It
is believed that the use of this protocol, rather than exclusively utilizing the screening instru-
ments, offers more reliable risk rates and allows greater refinement in triage, helping mostly by
establishing referral criteria for mental health professionals. This difference is because it was
observed that the sociodemographic and clinical characteristics cited can increase the risk for
such symptoms/disorders by 15 to 40% by themselves.
Moreover, the integrated evaluation of the variables also enables establishing the priorities
for referral and determining the best intervention, considering the specificity and weight of
each risk factor.
This protocol can be used by any health professional in assisted applications or can be self-
administered by the patient. Its use is free, and the estimated application time is two minutes.
In the present study, the internal validity of this protocol, which was evaluated based on the
discriminatory power of the nomograms, was determined to be promising. The values of sensi-
tivity and specificity are good, and in according with others short instruments available in liter-
ature [18]. However, the practical applicability of this probabilistic protocol is being tested in a
current study, and the findings (external validity) may further endorse its relevance, thus
encouraging its use by cancer professionals and services. In addition, this protocol can be con-
sidered for other severe diseases that have depressive stigma similar to those of cancer and can
serve as an optional armamentarium to appropriately interfere in the depression of the
patients.
However, it must be noted that validated screening instruments and protocols are essential
tools for overcoming the various barriers that prevent the appropriate identification and refer-
ral of cases to health care treatment. Nevertheless, such tools do not suffice to overcome other
important challenges, such as a) the resistance of many patients who, despite being aware of
their emotional condition, refuse help and treatment at this level [50], and b) the difficulty of
access to and maintenance of specialized treatment, especially in underdeveloped countries
such as Brazil [51], which requires the mobilization of efforts at different levels to raise aware-
ness among these individuals and to improve health policies.
Conclusions
The prevalence of the disorders under study is extremely high in cancer patients. The use of the
proposed protocol and nomogram can facilitate rapid and wide screening, thus refining triage
and supporting the establishment of criteria for referral to mental health professionals so that
patients can be properly diagnosed and treated.
Supporting Information
S1 Fig. Calibration of measures through the convergence graphics (data, depression con-
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